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Abstract
Background: Overweight/obesity are strongly implicated in breast cancer development, and weight gain post-
diagnosis is associated with greater morbidity and all-cause mortality. The aim of this study was to describe the
prevalence of overweight/obesity and the pattern of weight gain after diagnosis of breast cancer amongst
Australian women.
Methods: We collected sociodemographic, medical, weight and lifestyle data using an anonymous, self-
administered online cross-sectional survey between November 2017 and January 2018 from women with breast
cancer living in Australia. The sample consisted mainly of members of the Breast Cancer Network Australia Review
and Survey Group.
Results: From 309 responses we obtained complete pre/post diagnosis weight data in 277 women, and calculated
pre/post Body Mass Index (BMI) for 270 women. The proportion of women with overweight/obesity rose from
48.5% at diagnosis to 67.4% at time of survey. Most women were Caucasian with stage I-III breast cancer (n = 254)
or ductal carcinoma in situ (DCIS) (n = 33) and mean age was 59.1 years. The majority of women (63.7%) reported
they had gained weight after diagnosis with an average increase of 9.07 kg in this group. Of the women who
provided complete weight data, half gained 5 kg or more, 17.0% gained > 20 kg, and 60.7% experienced an
increase in BMI of >1 kg/m2. Over half of the women rated their concern about weight as high. Of those women
who gained weight, more than half reported that this occurred during the first year after diagnosis. Two-thirds
(69.1%) of women aged 35–74 years gained, on average, 0.48 kg more weight per year than age-matched controls.
Conclusions: Although the findings from this survey should be interpreted cautiously due to a limited response
rate and self-report nature, they suggest that women in Australia gain a considerable amount of weight after a
diagnosis of breast cancer/DCIS (in excess of age-matched data for weight gain) and report high levels of concern
about their weight. Because weight gain after breast cancer may lead to poorer outcomes, efforts to prevent and
manage weight gain must be prioritized and accelerated particularly in the first year after diagnosis.
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Background
Breast cancer is the most common cancer in women
worldwide and in Australia [1–3]. There were over 2
million new cases of breast cancer (BC) globally in 2018,
with this figure expected to rise to over 3 million by
2040 [3], by which time Australia expects to diagnose
more than 25,000 new cases annually [2]. Obesity is a
known risk factor for BC, particularly for post-
menopausal women [4]. Obesity after menopause (from
weight gain during either the premenopausal or post-
menopausal years) is directly related to an increased
relative risk of BC of 1.11 per 5 kg increase in weight [5].
Obesity at diagnosis is associated with worse BC sur-
vival and all-cause mortality rates and may increase the
risk of cancer recurrence by 30–40% [1, 6]. Furthermore,
weight gain is common after BC diagnosis, and may in-
crease the risk of disease recurrence and mortality and
have a negative impact on quality of life [1]. Weight gain
after BC diagnosis is thought to be multifactorial and
may be related to the use of systemic treatment, younger
age at diagnosis, as well as changes in lifestyle [1, 7].
Given the growing population of BC survivors and the
link between weight gain and adverse health outcomes,
research into weight after BC is of critical importance.
The prevalence of weight gain after BC in Australia
has not been adequately quantified. One prospective co-
hort study conducted in Queensland, in women who
had been diagnosed with early breast cancer, described
an increase in the proportion of women who were over-
weight/obese from 57% at diagnosis to 68% over 6 years
[8]. However, there is no national data currently avail-
able and few population studies exist [9]. The aim of this
study was to describe the prevalence of self-reported
overweight and obesity before and after a diagnosis of
BC or Ductal Carcinoma in Situ (DCIS).
Methods
Study design and inclusion criteria
A cross-sectional self-administered anonymous survey
was conducted in Australia between November 2017
and January 2018 using Qualtrics® online survey software
[10]. Any woman living in Australia who self-identified
as having BC was eligible to complete the survey. A copy
of the Participant Information Sheet was provided elec-
tronically via a link on the survey website prior to start-
ing the survey, and women were informed that consent
was implied upon commencing the survey. This method
of consent was approved by the Human Research Ethics
Committee (See below for details). The sample included
members of the Breast Cancer Network Australia
(BCNA) Review and Survey Group comprising BCNA
members who had agreed to receive emails about re-
search studies. Limiting research at BCNA to the Review
and Survey group allows researchers to access women
who are engaged in the research process, while protect-
ing other BCNA members from frequent research re-
quests. The Review and Survey Group (n = 1857)
represents approximately 2% of all BCNA members and
is one of the largest breast cancer consumer groups
available for research in Australia, representing an im-
portant source of feedback for the research community.
The survey was emailed to 1835 members on Decem-
ber 5th, 2017 and a reminder email sent January 15th,
2018 (Appendix). A smaller sample (n = 26) was also
drawn from online communities (women’s health
organization social media pages and online breast cancer
support groups in Australia) or through word of mouth
during November and December 2017. Ethics approval
for this study was provided by the Human Research Eth-
ics Committee, Western Sydney University (H12444,
October 2017).
Survey instrument
The survey was developed after reviewing previous lit-
erature on weight after BC and was subsequently revised
to include feedback from six BCNA representatives and
several health researchers. The 60-item survey included
questions on the sociodemographic characteristics, med-
ical details such as diagnosis and treatment, lifestyle
habits, weight status, and weight management. Details of
the survey questions are outlined in the Appendix. In
this paper, we report on change in weight from time of
diagnosis to time of the survey.
Weight after diagnosis
Women were asked to self-report their weight in kg at
the time of diagnosis, and current weight and height (in
meters). Body Mass Index (BMI) was calculated from
weight and height as weight/height2. The pattern of
weight since diagnosis was also assessed as “gained
weight overall”, “lost weight overall”, “weight stable” or
“weight has fluctuated a great deal”. We devised an un-
validated 11-point Likert scale to evaluate concern about
weight (using the question “Please rate how concerned
you have been over your weight in the last 12 months”)
ranging from 0 (not at all concerned) to 10 (very con-
cerned). We further characterized these data into four
categories according to the Likert score: No concern (0),
A little concerned (1–3), Somewhat concerned (4–7),
Very concerned (8–10). Weight at diagnosis was re-
ported by 90% of total respondents (277 women) and
current weight by 95% of respondents (293 women).
Statistical analysis
IBM SPSS® statistics package version 23 [11] and Stata®
statistical software version 13.11 [12] were used to
analyze the data presented in this report. We used de-
scriptive statistics to analyze diagnoses, treatments
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received, and health provider visits of respondents in
percentages. Women who did not self-report their
weight were excluded from analyses relating to weight.
We calculated the percentage of women who were cur-
rently overweight (BMI > 25 and < 30) or obese
(BMI > 30) and compared this to the proportion who
were overweight/obese at time of diagnosis. Current and
pre-cancer weight and BMI were reported as a mean
and standard deviation. We calculated the number and
percentage of women whose BMI changed from healthy
(< 25) to unhealthy (BMI > 25) from diagnosis to time of
survey, as well as women who reported an increase of
BMI of greater than 1 kg/m2. Tests for skewness and
kurtosis for weight, BMI at diagnosis, current weight
and BMI, and weight gain, indicated that our data had a
normal distribution.
We described the self-reported weight gain pattern as
percentage of body weight at diagnosis, the proportion
of women who gained > 5 kg, and the proportion of
women who gained 5–10% and > 10% of body weight.
We used a paired t-test to compare weight and BMI at
diagnosis and weight and BMI at time of survey, and
Fisher’s exact test to explore the association between
current BMI classification and weight concern. To test
the relationship between weight gain and time since
diagnosis (and therefore the hypothesis that weight gain
increases with time) we performed a Pearson’s correl-
ation. We also categorized time since diagnosis into 2.5
year blocks and ran a one-way analysis of variance
(ANOVA) exploring the relationship between time since
diagnosis and weight gain in the following groups of
women: women who reported gaining weight overall,
and who had self-reported weight gain > 5%. We ex-
plored the relationship between amount of weight gain
and weight gain concern using the Pearson’s chi-squared
test.
We calculated the mean weight gain per year in our
sample as total weight gain divided by time since diagno-
sis in years. We removed one outlier who reported gain-
ing 10.5 kg per year over 2 years and reported rate of
weight gain across age groups in five-year brackets (see
Fig. 3 and Table 5).
Comparing rate of weight gain against normative data
To compare weight gain in our sample against norma-
tive data in the Australian population, we used data the
AusDiab study. The AusDiab study is a large national,
longitudinal population-based study involving > 11,000
adults aged 25 years and older. Baseline data collection
for the AusDiab study occurred during 1999–2000, with
a subsequent 5-year follow-up (during 2004–2005) [13].
The AusDiab study reported the following mean weight
gains per year at 5-year follow-up (2004–5): 700 g per
year for 25-34yo, 500 g for 35-44yo, 380 g for 45-54yo,
140 g for 55-64yo and 0 g for 65-74yo). For each re-
spondent in our study for which we could calculate a
yearly weight gain, we compared this weight gain with
the mean weight gain from AusDiab corresponding to
the age group of the respondent by subtracting the Aus-
Diab weight gain from the weight gain reported by that
respondent in our study. We used Pearson’s chi-squared
testing to compare the numbers of women who gained
in excess of the rates reported in the AusDiab study
across the age groups described above.
Results
Survey response
Of the 1857 BCNA members, 283 (15%) responded to
the survey. A further 26 women responded to the survey
from other channels giving a total of 309 responses.
Sample characteristics
Demographic characteristics of respondents are de-
scribed in Table 1. The majority of women were Cauca-
sian (92.5%, n = 285) with a mean age of 59.1 years
(SD = 9.5, range 33–78, n = 298). Characteristics were
similar across BCNA members and non-BCNA respon-
dents with no differences between these groups on Pear-
son’s Chi-squared test. The majority of women were
either premenopausal (43%) or perimenopausal (12%) at
the time of diagnosis. Of the 145 women who were still
menstruating at time of diagnosis, 68% were premeno-
pausal and became postmenopausal, 18% were peri-
menopausal and became postmenopausal, while a
smaller number (13%) remained perimenopausal.
Clinical characteristics
Diagnoses
Clinical diagnoses of the respondents are summarized in
Table 2. The majority of women (82%, n = 252) had been
diagnosed with non-metastatic BC. The mean time since
diagnosis of BC was 8.2 years (SD 5.12, range 1–32 years)
and mean age at diagnosis was 50.9 years (SD = 9.02,
range 29–74).
Treatments
Women reported receiving a range of BC treatments in-
cluding surgery and/or radiation, and axillary, systemic
and hormonal treatments, which are detailed in Table 2.
The most commonly visited health care providers,
within the last 12 months, were breast surgeons (n =
172), physiotherapists (n = 124) and medical oncologists
(for chemotherapy) (n = 119). On average, respondents
(n = 247) had visited three health care providers in the
last 12 months (range, 1–10). For women with DCIS, 18
(53%) had a mastectomy, 17 (50%) had received radi-
ation and 19 (56%) had received hormonal treatment.
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Weight change
Table 3 and Fig. 1 describe weight and BMI change
patterns in our respondents. Mean self-reported
weight at time of diagnosis was 71.24 kg (SD 14.01,
range 47–158, n = 277) and at time of survey was
76.08 kg (SD 15.37, range 46–150, n = 293). Mean
self-reported current BMI was 28.02 kg/m2 (SD = 5.88,
n = 285) and mean pre-cancer BMI was 26.37 kg/m2
(SD = 5.92, n = 271). Just under half of women (48.5%)
were overweight or obese at time of diagnosis, but by
the time of the survey this proportion had risen to
67.3%. This increase was most marked for women
who were obese, from 17.0% at diagnosis to 31.9% at
the time of the survey. Mean weight gain was 4.50 kg
(SD 8.90, n = 277).
Table 1 Demographic characteristics of survey respondents
Description N
(responses)
%
State (n = 309)
Australian Capital Territory 14 4.5%
New South Wales 91 29.5%
Northern Territory 0 0.0%
Queensland 48 15.5%
South Australia 28 9.1%
Tasmania < 5 1.0%
Victoria 95 30.7%
Western Australia 30 9.7%
Education (n = 307)
High school- year 10 30 9.8%
High school- year 12 35 11.4%
Vocational College 55 17.9%
Bachelor’s degree 90 29.3%
Postgraduate degree 97 31.6%
Ethnicity (n = 308)
European/Anglo Saxon/Caucasian 285 92.5%
Asian 5 1.6%
Oceanic (incl. Australian and New Zealand first
peoples, Polynesian and Micronesian)
13 4.2%
North/South/Central American < 5 0.7%
Mixed ethnicity < 5 0.7%
Indian < 5 0.3%
Employment (n = 308)
Employee 140 45.5%
Self-employed 33 10.7%
Home duties/caring for children or family 15 4.9%
In education (going to school, university, etc.) < 5 1.3%
Doing voluntary work 10 3.3%
Unable to work because of illness 6 2.0%
Unable to work for other reasons < 5 0.3%
Retired 99 32.1%
Relationship Status (n = 309)
Single 39 12.6%
Married/de facto (living with partner) 230 74.4%
In a relationship (not living with partner) 7 2.3%
Divorced/separated 24 7.8%
Widowed 9 2.9%
Table 2 Diagnoses and treatments received
Description N % Missing n (%)
Diagnoses 1 (0.3%)
Ductal Carcinoma In Situ (DCIS) 33 10.7%
Localised breast cancer 252 81.8%
Metastatic breast cancer 14 4.6%
Inflammatory breast cancer <5 0.7%
Other including second primary 7 2.3%
Treatment to the Breast 2 (0.6%)
Lumpectomy alone <5 0.7%
Lumpectomy and radiation 129 42.0%
Mastectomy alone 74 24.1%
Mastectomy and radiation 71 23.1%
Lumpectomy and mastectomy alone 10 3.3%
Lumpectomy, mastectomy and radiation 16 5.2%
Double mastectomy 5 1.6%
Reconstruction after mastectomy (n = 164)
No 84 51.2%
Immediate 37 22.6%
Delayed 43 26.2%
Treatment to the Axilla (n = 167) 13 (7.8%)
Sentinel node biopsy only 24 15.6%
Axillary dissection +/− Sentinel node
biopsy
56 36.4%
Axillary dissection +/− Sentinel node
biopsy + radiation
72 46.8%
Radiation only <5 1.3%
Intravenous Systemic Therapy
Chemotherapy without Herceptin 164 53.1%
Herceptin only < 5 0.7%
Chemotherapy + Herceptin 46 14.9%
None/not reported 97 31.4%
Hormonal Treatments
Tamoxifen alone 58 18.8%
Other 146 47.3%
None 105 34.0%
Current use of hormone therapy
Yes 125 40.5%
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One fifth (54/270, 20.0%) of women went from being
in the healthy weight range at diagnosis (BMI <25), to
an unhealthy weight range (BMI > 25), a further 14.8%
moved from the overweight range into obesity, and
60.7% (164/270) of women reported an increase in BMI
greater than 1 kg/m2 (Table 3). Of note, a small propor-
tion of women lost weight whereby 5.6% of women went
down at least one BMI category (Table 3).
There was a statistically significant difference between
both weight and BMI at diagnosis and current weight
Table 3 Weight change patterns after diagnosis of breast cancer
Description N % Missing
N (%)
Self-reported weight gain pattern 17 (5.5%)
Weight gain 186 63.7%
Weight loss 38 13.0%
Stable 48 16.4%
Fluctuated 20 6.9%
Calculated % weight change from baseline 32 (10.4%)
Weight loss 62 22.4%
<5% weight gain 53 19.1%
5–10% weight gain 64 23.1%
>10% weight gain 98 35.4%
Calculated weight change 32 (10.4%)
Weight loss 62 22.4%
Weight gain up to 5 kg 75 27.1%
Weight gain ≥5 kg and < 10 kg 75 27.1%
Weight gain ≥10 kg and < 20 kg 18 6.5%
Weight gain >20 kg 47 17.0%
Timing of weight gaina (n = 186)
<6 months post diagnosis 47 25.3%
6–12months post diagnosis 60 32.3%
12–18 months post diagnosis 38 20.4%
18–24 months post diagnosis 16 8.6%
2–3 years post diagnosis 14 7.5%
>3 years post diagnosis 11 5.9%
Change in BMI classification from time of diagnosis to time of survey (n = 270)
Weight gain Healthy to overweight 49 18.2%
Overweight to obese 40 14.8%
Healthy to obese 5 1.9%
Underweight to healthy weight <5 1.5%
Underweight to overweight <5 0.4%
Stable Remained in healthy range 69 25.6%
Remained in overweight range 39 14.4%
Remained in obese range 40 14.8%
Remained in underweight range 8 3.0%
Weight loss Healthy weight to underweight 3 1.1%
Obese or overweight to healthy weight 6 2.2%
Overweight to underweight <5 0.4%
Obese to overweight 5 1.9%
athis question was answered only if respondents had selected “gained weight overall”; BMI=Body Mass Index; Underweight = BMI < 20; Healthy weight = BMI > 20
and < 25; Overweight = BMI > 25 and < 30; Obese = BMI > 30
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and BMI (mean difference 4.50 kg, CI 3.45–5.55,
p = 0.00, n = 277 and 1.64 kg/m2, CI 1.24–2.04, p = 0.00,
n = 270 respectively). The majority of respondents
(63.7%) reported they had gained weight overall after
diagnosis. This is consistent with the self-reported
weight gain in our study, where 58.5% of women gained
> 5% of pre-diagnosis body weight. Half of the respon-
dents had gained more than 5 kg, with 17.0% reporting
gains of over 20 kg of weight.
Of the women who reported gaining weight overall
and for whom we had complete weight data (n = 175),
87.4% (153/175) gained ≥5 kg of weight, and 54.9%
gained > 10% of pre-diagnosis body weight. Average
weight gain in this group was 9.07 kg. Women reported
that weight gain predominantly occurred within the first
2 years of diagnosis (86.6%) with 57.5% reporting that
weight gain mostly occured within the first 12months.
Weight gain was not correlated with time since diagnosis
(n = 173, r = .114, p = 0.14). There was no difference in the
amount of weight gain by time since diagnosis when this
was examined in blocks of 2.5 years, in women who had
reported weight gain overall (n = 175, p = 0.26), and in
women who self-reported weight gain of greater than 5%
of diagnosis body weight (n = 162, p = 0.27). (Table 4).
Three quarters (74.7%, n = 68/91) of women who
were currently obese reported very high levels of con-
cern about their weight, compared to a quarter of
women in the healthy weight range (25.9%, n = 21/81)
(p = 0.00). Women who had gained more weight were
more likely to express high levels of concern about
Fig. 1 Change in BMI classification after diagnosis of breast cancer. BMI=Body Mass Index
Table 4 Weight gain by time in years since diagnosis
Women who had gained >5% weight (n = 162) Women who reported weight gain pattern overall (n = 175)
Mean weight gain (kg) SD Freq. Mean weight gain (kg) SD Freq.
Time since diagnosis (years)
< 2.5 9.00 (6.51) 6 8.14 (6.36) 7
2.5–5 8.42 (4.57) 23 7.36 (4.73) 28
5–7.5 9.27 (5.27) 54 8.90 (5.47) 56
7.5–10 9.15 (5.42) 22 8.43 (5.64) 24
> 10 11.21 (7.14) 57 10.38 (7.37) 60
SD Standard Deviation, Freq Frequency
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their weight. Of the women who gained 5–10% of
weight and > 10% of weight, 54.8 and 78.4% reported
being very concerned about their weight respectively,
compared with 22.5% of women who had gained less
than 5% of their diagnosis weight (X2, (9, n = 263) =
67.6137, p = 0.000). (Fig. 2).
Rate of weight gain, and comparison with normative data
On average, women in our study gained 0.64 kg per year
(n = 270, SD = 1.76, range − 8 to 10.5) (see Table 5). For
women aged 25–74 years (the age range for which we
have normative data), the mean weight gain in excess of
age-matched controls was 0.48 kg per year (n = 235, SD =
1.67, range − 8.38 to 7.62). Overall, two thirds (69.8%) of
women in our sample gained in excess of normative
weight gain in the AusDiab study, including 25.1% of
women who gained > 1 kg per year in excess of norma-
tive rates of weight gain. There was no difference be-
tween age groups with regard to the number of women
who gained in excess of normative weight gain (X2, (n =
235) = 6.6929, p = 0.153). See Fig. 3 for mean weight gain
in excess of normative data for each age group. There
was only one woman in the 25–34 age group; to pro-
tect confidentiality we did not include her data in
Table 5 or Fig. 3.
Discussion
This is the first national survey conducted in Australia
to describe weight after breast cancer. The distribution
of responses according to state and territory in our sur-
vey is broadly consistent with the incidence of BC in
these regions [14] indicating our sample was nationally
representative by location. We found that two-thirds of
our respondents were currently overweight or obese,
with the majority of women reporting they had gained
weight after diagnosis, mostly within the first 12 months
and at a substantial self-reported average of 9.07 kg. Of
note, the proportion of women who were overweight or
obese rose sharply from 48% at time of diagnosis to 67%
at the time of the survey, with the proportion of women
who were obese almost doubling from 17 to 32%. The
majority of women gained weight in excess of the rates
reported in age-matched controls without breast cancer.
This equated to an average of an additional 2.42 kg over 5
years. A very small proportion of women (5.6%) changed
from a higher to lower BMI category. It would be of inter-
est to explore such findings to enquire whether this is a
result of intended weight loss or treatment related effects.
The proportion of women who were overweight or
obese in our study is consistent with those from a pro-
spective study of 287 women conducted in Queensland,
Australia which compared weight gain after diagnosis of
Fig. 2 Weight gain concern and current BMI classification (n = 285). BMI=Body Mass Index
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early BC. By 6 years, 68% of women in the cohort were
overweight or obese, [8] which is remarkably similar to
our findings. Median weight gain for study participants
between 6 and 72months was 0.7 kg, and mean BMI in-
crease was 0.2 kg/m2. The authors of the cohort study
compared the weight gain in the BC cohort with age-
matched controls and reported a significant difference,
with only 50% of age-matched controls being overweight
or obese. One other population study has been pub-
lished from Shanghai on obesity and clinical outcomes
of 4561 Chinese women [9]. In that study, mean weight
gain at 18 months post-diagnosis was 1.7 kg. Mean
weight gain in our study was significantly higher at 4.5
kg which could be explained by the longer time since
diagnosis in our study. Further, the mean weight gain in
women who had gained weight overall in our study is
substantially higher than what is reported in the Austra-
lian cohort study (9.07 kg vs 5.3 kg) although we note
that the mean time since diagnosis in our study is 8.2
years, while the cohort study used a 6-year follow-up.
Our study provides additional data on weight gain after
BC in Australia, over a wider time frame and location
and with a larger sample size, and suggests that the
problem of weight gain after BC may be larger than pre-
viously anticipated.
A large international review found that 50–96% of
early stage BC patients experience weight gain during
treatment in the range of 1.7 kg to 5.0 kg in the 18
months following treatment [15]. Of those who gained
weight, 27% gained 2 kg to 5 kg and 24% gain 5 kg or
more in the 18 months following treatment. This com-
pares to our study where 50.55% reported gaining 5 kg
or more mainly in the first 18 months after treatment,
again suggesting that weight gain after BC is a greater
problem than previously thought.
Our findings are of concern because weight gain pre-
and post- BC diagnosis have both been associated with
increased morbidity and mortality. Whilst those at
heaviest weight at diagnosis appear to carry an increased
risk, even those within the healthy weight range at diag-
nosis face increased risk following weight gain [16]. Data
from the Nurse’s Health Study in the USA showed the
risk of cancer recurrence was increased by 40% following
a mean weight gain of 2.7 kg, and by 53% following
mean weight gain of 7.7 kg, [17] with the greatest in-
creased risk in those of healthy weight at diagnosis. An-
other observational study of 3993 women, each 5 kg gain
in weight post-diagnosis was associated with a significant
12% increase in all-cause mortality, 13% increase in BC-
specific mortality, and 19% increase in cardiovascular-
disease mortality (all p < 0.05) after an average 6.3 years
follow-up after diagnosis [18]. Extrapolating from these
results indicate that approximately half of our cohort
face a significant increase in cancer recurrence and mor-
tality due to weight gain > 5 kg, and that efforts to pre-
vent weight gain in women diagnosed with BC need to
be accelerated and prioritized.
Our findings indicate high levels of concern about
weight, particularly in women who were currently over-
weight or obese. Weight gain exacerbates the significant
body image concerns already faced by BC survivors, has
a negative impact on quality of life, and may be a cause
of distress if it was unanticipated [19]. We did not ex-
plore quality of life or levels of distress in our cohort,
but additional research in this area appears to be
warranted.
Although the proportion of overweight and obesity in
our survey is similar to national data for women aged
45–64 (which ranges from 61 to 69%) [20], the majority
of our respondents were from a higher socioeconomic
group with 60% having a Bachelor’s degree qualification
or higher, and 56% being employed or self-employed.
National data indicate rates of overweight and obesity
for women in the highest socioeconomic group as low as
48% [20] indicating that the proportion of overweight
and obesity in our respondents is higher than would be
expected of women with similar demographic character-
istics. Finally, when compared to age-matched controls
from the AusDiab study, 69.8% of women in our survey
gained in excess of normative weight gain, indicating
that the weight gain experienced within our sample is
unlikely to be explained by weight gain that would nor-
mally be experienced as women age and progress
through the menopausal transition.
This study also highlights the importance of treatment
teams being aware that weight gain, particularly in the
first year after treatment, is an important issue, which
would benefit from interventions such as diet and exer-
cise. In this study, 186 of 292 patients (63.69%) gained
weight, 57% gained within the first 12 months and 77%
within 18 months. The timing of weight gain within the
first year of treatment has been reported by others [21,
22]. Recently, the Clinical Oncological Society of
Australia has strongly advocated for exercise to be em-
bedded as part of standard practice in cancer care and
advised all members of the multidisciplinary cancer team
to promote physical activity, encourage patients to
Table 5 Mean weight gain per year in each age group, and
proportion who gained in excessive of normative rates
Age (years) Mean weight gain per year
in kg in our study (SD)
% who gained in excess
of AusDiab data
35–44 (n = 21) 1.59 (1.16) 81.0
45–54 (n = 72) 0.75 (2.35) 61.1
55–64 (n = 100) 0.50 (1.47) 76.0
65–74 (n = 42) 0.39 (0.94) 64.3
All (n = 235) 0.64 (1.76) 69.8
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adhere to exercise guidelines and refer patients to an
accredited exercise physiologist or physiotherapist with
experience in cancer care [23]. All people with cancer
should progress towards and, once achieved, maintain
participation in at least 150 min of moderate intensity or
75 min of vigorous-intensity aerobic exercise (e.g. walk-
ing, jogging, cycling, swimming) each week; and two to
three resistance exercise (i.e. lifting weights) sessions
each week involving moderate-to-vigorous-intensity ex-
ercises targeting the major muscle groups. In women
with breast cancer, there appears to be a window of op-
portunity within the first 18 months to initiate weight
management interventions in order to prevent excessive
weight gain.
Strengths of this survey include the higher than ex-
pected response rate from the BCNA Review and Survey
Group. According to the Research and Evaluation Man-
ager, BCNA (email communication 3 Oct 2017), the typ-
ical response rate in this group is 10%, whereas the
response to our survey was 15%. However, given that the
Review and Survey Group represents only approximately
2% of all BCNA members, the validity of our findings is
somewhat limited but important to highlight particularly
to clinicians managing patients with breast cancer to en-
sure they encourage and more importantly “prescribe”
an exercise program after cancer treatment.
We achieved a broadly nationally representative sample
according to location. The percentage of respondents
from each Australian State and Territory is similar to na-
tional averages on BC incidence as described by the Aus-
tralian Institute of Health and Welfare cancer data [14].
Limitations of this survey included its self-report na-
ture. In general, people tend to underestimate their
weight and overestimate their height with self-reporting
[24]. Social desirability bias and response bias may play a
part in this inaccuracy. In our cross-sectional study, it is
possible that recall bias led to further underestimation of
pre-diagnosis weight, therefore inflating the reported
weight gain. Additionally, a small proportion of women
chose not to report their weight in this survey (10% for
pre-diagnosis weight, and 5% for current weight). How-
ever, using self-reported weight and height is simple and
readily accessible, and is considered less intrusive than
objectively measured weight, therefore allowing us to
conduct a nation-wide survey and increase the response
rate. The true prevalence of weight gain after BC may be
different to that found in our survey as women who had
gained weight after BC may have been more likely to re-
spond to our survey compared to women who had not
gained weight. Nevertheless, the prevalence reported in
our survey is remarkably similar to that in prospective
cohort studies, suggesting that our data is robust. There is
an urgent need to further understand the predictors of
weight gain in women with BC. Further planned analyses
from our data will include analysis of the predictors of
weight gain in our sample, including use of chemotherapy,
hormonal therapy, and menopausal stage at diagnosis.
We acknowledge that the inability to provide matched
controls in this survey is a limitation. However, we were
able to retrospectively match women by age to controls
from the 2005 AusDiab study and found that women
gained in excess of normative data, although limitations
of our comparison is that we could not locate more re-
cent data on normative rates of weight gain, and the
duration of weight gain varied in our sample. Further-
more, that our findings are remarkably similar to a
Fig. 3 Mean weight gain per year in excess of normative data, by age (n = 234)
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cohort study in the state of Queensland in Australia [8]
we believe our findings are a reliable representation of
breast cancer survivors. Additionally, it would be of
interest to look at change in weight over time and ac-
cording to menopausal status in matched controls. As
such this will be examined in a future manuscript.
We were unable to report on the proportion of fat
mass gained relative to muscle mass lost, know as sarco-
penia. Sarcopenia is common in many women even
without body weight change, with 74% of women in-
creasing total body fat relative to lean muscle, [25] with
an increased risk from tamoxifen use [26] and common
after reduced activity during chemotherapy. Such
changes are associated with the development of comor-
bidities such as diabetes and cardiovascular disease,
thereby influencing long-term survival [27]. Excess adi-
posity is also associated with poorer prognosis through
increases in adipose derived circulating estrogens and
via increased circulating levels of insulin, insulin-like
growth factor and leptin [28].
Another potential weakness of our study is that the
vast majority of survey respondents were Caucasian,
thereby limiting the generalizability of our data to
women from other ethnicities but provides an important
perspective over and above the Shanghai study where
patients were less overweight or obese at diagnosis and
whose diet differed from a Western diet. Previous re-
search from the United States, has shown when com-
pared with non-Hispanic whites, Hispanic and black
women have higher rates of obesity (21.8%, compared
with 29.4 and 39.2%, respectively), lower rates of meet-
ing physical activity guidelines (19.0%, compared with
12.5 and 17.5%, respectively), and lower intake of three
or more servings of fruit and vegetables per day (27.7%,
compared with 19.7 and 21.9%, respectively). Under-
standing this in the Australian context will be an im-
portant component of future research [29].
Additionally, although the response rate from the
BCNA Review and Survey Group was higher than what
is typically seen, this represented a very small proportion
of all BCNA members, limiting the validity of our find-
ings. Notwithstanding such limitations, the demograph-
ics in our sample (who were predominantly well-
educated and either employed or self-employed) are not
inconsistent with national data indicating that the inci-
dence of breast cancer is highest in the areas with high-
est socioeconomic advantage [30]. Additionally, the
demographics of the BCNA respondents and non-BCNA
respondents were similar, suggesting that our findings
can be extrapolated to other BCNA members.
Conclusion
This is the first national survey of Australian women to
describe weight gain after diagnosis of BC. Survey
respondents gained a subtantial amount of weight (mean
of 9.07 kg), with a doubling of the proportion of women
living with obesity. This is coupled with high rates of
concern about weight after breast cancer. Given that
weight gain after BC may lead to poorer outcomes, there
is a need to prioritize and accelerate efforts to assist
women to prevent and manage weight gain after BC,
particularly during the first 12 months after diagnosis.
Appendix
Specific demographic, medical, menopausal and
lymphoedema details requested in the survey
Demographic characteristics.
State of residence, highest level of education, ethnicity,
employment status, relationship status, current age and
age at diagnosis were included to describe the character-
istics of women.
Medical details.
Women were asked about their diagnosis, treatments
received including treatments received to the axilla, the
number of lymph nodes removed, whether they had a
reconstruction, use of hormonal treatments, menopausal
state (at diagnosis and current), presence of other med-
ical conditions and symptoms such as hot flushes and
the presence and severity of lymphoedema.
Women were asked to describe the type of breast can-
cer they were diagnosed with as either “ductal cancer in-
situ (DCIS)”, “localised stage breast cancer (where your
breast cancer is contained within your breast and/or
lymph nodes), “metastatic breast cancer (breast cancer
that has spread beyond the breast tissue and lymph
nodes to distant parts of the body, such as the bones,
liver and lungs; also called advanced, secondary or stage
four) “ or “inflammatory breast cancer. “For conveni-
ence, inflammatory breast cancer and metastatic breast
cancer were then combined and referred to as advanced
breast cancer. Women were also asked to indicate the
treatments they received such as “Lumpectomy alone”,
“Lumpectomy and radiation”, “mastectomy alone”,
“mastectomy and radiation”, “removal of lymph nodes”,
“chemotherapy”, “hormonal therapy”, “targeted therapy
(Herceptin)”, and “other”. As chemotherapy is invariably
not provided to women with DCIS, we recoded the diag-
nosis as “localised” if a woman indicated that she had re-
ceived chemotherapy.
Menopausal state at the time of diagnosis was assessed
as either “Premenopausal (regular periods with no
menopausal symptoms such as hot flushes)”, “Perimeno-
pausal/in the menopausal transition (no periods for at
least 2 months, plus hot flushes)”, “Postmenopausal (no
periods for at least 12 months)” or “Previous surgical
menopausal (both ovaries or uterus/womb had been re-
moved).” Participants who indicated they were premeno-
pausal or perimenopausal at the time of diagnosis were
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asked if they were having periods before breast cancer
treatment and to describe what has happened to their
periods now; “they have stopped”, “they stopped and
then started again”, “they have become more irregular”,
“no change” or “other”.
Lymphoedema severity was defined as either “no prob-
lem (no noticeable swelling)”, “mild (soft swelling that is
not obvious to others and comes and goes)”, “moderate
(swelling with occasional hardness in some areas that is
obvious to others and is always present)”, “severe (pro-
fuse swelling with thickened skin, constant hardness,
and a very large, heavy arm that is extremely obvious to
others and is always present) as described elsewhere [7].”
Lifestyle habits.
Women were asked if they had tried the following spe-
cific diets in the previous 12months: Atkins diet (low
carbohydrate), 5:2 diet (eat what you want 5 days a week,
send your body into starvation mode for 2 days),
Paleolithic diet, Dukan diet (High-protein, low-carb),
Vegetarian diet, Vegan diet, Weight Watchers diet, Raw
food diet, Ultra low-fat diet, Zon diet, Cambridge diet
(very low calories), South Beach diet (low-GI), Other.
They were asked if they ate at least the recommended
serves of fruit and vegetables a day (2 fruit, five vege-
table) with answer options of Yes/No. Self-perceived diet
quality was assessed as Excellent/Very Good/Good/Fair/
Poor. Smoking was assessed as current cigarrete use
(Never smoked/Ex smoker/Recently quit ex smoker
(smoked in the last 3 months)/Current smoker) and
current smokers were asked to indicate the number of
cigarettes they smoked each day. Alcohol intake was
assessed as Non drinker/1–7 standard drinks a week/8–
14 standard drinks a week/> 14 standard drinks a week)
and a guide to standard drink sizes was provided. The
validated Weight Self Efficacy Scale (WEL-SF) [3] was
used to evaluate how confident women now felt about
being able to successfully resist the desire to overeat in
eight different situations on an 11-point Likert scale
from 0 (not confident at all) to 10 (very confident). We
further dichotomised the responses into “Not confident”
(0–4) and “Confident” (5–10). Physical activity levels
were calculated according to the number of 20-min ses-
sions of less vigorous exercise or more vigorous exercise
a week, given a weighting and described in terms of
MET (metabolic cost) minutes where MET minutes less
than 80 were coded as no physical activity, 80 to 400 as
low, 400 to 560 as moderate and more than 560 as high.
A value of 4 METs was given to moderate physical activ-
ity and 7.5 to vigorous physical activity [26].
Weight management.
Experiences with a range of weight loss interventions
(Exercise, Diet – various: Intermittent fasting, etc.
(please specify), Meal replacements e.g. shakes, Medica-
tion, Weight loss supplements/products, Surgery (please
specify), Online program e.g. 12 week Body Transform-
ation, Social support, Weight loss program e.g. Jenny
Craig, Psychological treatments such as CBT (Cognitive
Behavioural Therapy) and the perceived effectiveness of
the interventions on was described using a five-point
Likert scale from 1 (not at all effective) to 5 (very effect-
ive). The responses were further dichotomized into 1 to
2 (not effective) and 3 to 5 (effective). Women were also
asked about perceived barriers and facilitators to suc-
cessful weight loss and weight maintenance, and what
they believed should be research priorities in this area.
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